Home>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> NAFLD & NASH>>3-Epideoxycholic Acid

3-Epideoxycholic Acid (Synonyms: EDCA)

Catalog No.GC49850

A secondary bile acid and an epimer of deoxycholic acid

Products are for research use only. Not for human use. We do not sell to patients.

3-Epideoxycholic Acid Chemical Structure

Cas No.: 570-63-8

Size Price Stock Qty
1 mg
$88.00
In stock
5 mg
$393.00
In stock
10 mg
$698.00
In stock
25 mg
$1,527.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

3-Epideoxycholic acid (EDCA) is a secondary bile acid and an epimer of deoxycholic acid .1 EDCA has been used as a steroidal host compound for the enantioselective purification of (2R,3S)-3-methyl-2-pentanol from its racemates via enclathration.2 Fecal levels of EDCA are decreased in patients with pediatric non-alcoholic fatty liver disease (NAFLD).1

1.Yu, J., Zhang, H., Chen, L., et al.Disease-associated gut microbiota reduces the profile of secondary bile acids in pediatric nonalcoholic fatty liver diseaseFront. Cell. Infect. Microbiol.11698852(2021) 2.Kato, K., Aburaya, K., Miyake, Y., et al.Excellent enantio-selective enclathration of (2R,3S)-3-methyl-2-pentanol in channel-like cavity of 3-epideoxycholic acid, interpreted by the four-location model for chiral recognitionChem. Commun. (Camb.)232872-2873(2003)

Reviews

Review for 3-Epideoxycholic Acid

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3-Epideoxycholic Acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.